Literature DB >> 33028568

Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor.

Maki Miwa1, Mikio Nakajima2, Richard H Kaszynski2, Hideaki Goto2.   

Abstract

A 45-year-old woman was admitted for diabetic ketoacidosis (DKA). Aggressive rehydration and continuous intravenous insulin resulted in improved blood glucose levels; however, metabolic acidosis persisted. One day prior to admission, the patient took a single dose of a sodium-glucose cotransporter 2 (SGLT2) inhibitor and this likely contributed to the prolonged euglycemic DKA. A single dose of this drug remained effective for over 100 hours as evidenced by massive excretion of urine glucose continuing long after blood glucose normalisation. SGLT2 inhibitor use should be refrained in cases in which DKA has already occurred as they may result in increasing severity or prolonged DKA. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diabetes; drugs: endocrine system; primary care

Mesh:

Substances:

Year:  2020        PMID: 33028568      PMCID: PMC7542622          DOI: 10.1136/bcr-2020-235969

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

2.  Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.

Authors:  Jenny E Blau; Sri Harsha Tella; Simeon I Taylor; Kristina I Rother
Journal:  Diabetes Metab Res Rev       Date:  2017-09-29       Impact factor: 4.876

3.  Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.

Authors:  Nahoko Kasahara-Ito; Hiroyuki Fukase; Yoichiro Ogama; Tomohisa Saito; Yasuhiro Ohba; Sumire Shimada; Yasuki Takano; Tomoko Ichihara; Kimio Terao; Noboru Nakamichi; Yuji Kumagai; Sachiya Ikeda
Journal:  Drug Res (Stuttg)       Date:  2017-04-20

4.  Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.

Authors:  Owais Rashid; Saad Farooq; Zareen Kiran; Najmul Islam
Journal:  BMJ Case Rep       Date:  2016-05-13

Review 5.  Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State.

Authors:  Maya Fayfman; Francisco J Pasquel; Guillermo E Umpierrez
Journal:  Med Clin North Am       Date:  2017-05       Impact factor: 5.456

6.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.

Authors:  Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch
Journal:  Diabetes Care       Date:  2015-06-15       Impact factor: 19.112

7.  Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.

Authors:  Yasuo Terauchi; Masahiro Tamura; Masayuki Senda; Ryoji Gunji; Kohei Kaku
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

8.  Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism.

Authors:  R Ghazvinian; A Gottsäter; J L Elf
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

9.  Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors.

Authors:  Michael Limenta; Christine S C Ho; Jalene W W Poh; Su-Yen Goh; Dorothy S L Toh
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).

Authors:  Kazunori Utsunomiya; Masayuki Senda; Seigo Kakiuchi; Hiroyuki Kameda; Masahiro Tamura; Yuji Kurihara; Ryoji Gunji; Shoko Fujii; Hisataka Fujiwara; Kohei Kaku
Journal:  J Diabetes Investig       Date:  2019-03-06       Impact factor: 4.232

View more
  1 in total

1.  SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.

Authors:  Fateen Ata; Zohaib Yousaf; Adeel Ahmad Khan; Almurtada Razok; Jaweria Akram; Elrazi Awadelkarim Hamid Ali; Ahmed Abdalhadi; Diaeldin Abdelgalil Ibrahim; Dabia Hamad S H Al Mohanadi; Mohammed I Danjuma
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.